Biotechnology

C4 Therapeutics begins a crucial study for its oral protein degrader, cemsidomide, offering new hope for heavily treated multiple myeloma patients.

Anavex Life Sciences adds AMEOS Group CEO Dr. Axel Paeger to its board, a strategic move signaling a push into European markets for its CNS therapies.

With a key drug in trials and a pipeline nearing the clinic, Foghorn Therapeutics brings in a seasoned financial leader to navigate its path to market.

The biotech firm slashed a major acquisition hurdle in a deal with HealthCare Royalty, signaling strong confidence in its cancer drug ZYNLONTA's future.

A Swiss firm begins human trials for a non-glucose dialysis solution, aiming to end a 30-year reliance on problematic treatments for kidney patients.

Arrotex secures rights to an innovative, FDA-approved nanotech eye drop, promising faster, simpler recovery for thousands of surgical patients.

A landmark partnership aims to slash BCI development costs from $100M to $5M, accelerating therapies and the quest for a human brain AI model.

With a major capital infusion, the biotech firm will accelerate its lead drug for Eosinophilic Esophagitis and expand its innovative Diffusphere™ platform.

The FDA is reviewing a new, more affordable alternative to the costly arthritis drug Orencia, potentially saving patients and the healthcare system billions.

Sōlaria Biō’s new study validates a microbe-based medical food, Bōndia™, offering a novel, science-backed approach to bone loss for millions of women.

With its NAD+ technology featured in Forbes, biotech brand Aramore is challenging marketing hype with scientific rigor and a vision for longevity.

ABLi Therapeutics reports its drug risvodetinib is the first to lower toxic alpha-synuclein levels in a Phase 2 trial, heralding a new era for patients.

enGene hits the road for key investor conferences, showcasing a promising non-viral gene therapy for a tough-to-treat bladder cancer. Will it succeed?

A new partnership will supply Japan's surging cell therapy sector with critical, GMP-grade materials, aiming to accelerate the path from lab to clinic.

INmune Bio will present key Phase III results for CORDStrom, a systemic cell therapy for the devastating rare skin disease RDEB. Will it be a breakthrough?

A novel implant activating the body's own pathways could offer a safer, more effective alternative to traditional hormone therapies for breast cancer.

Meet the three brilliant researchers whose work in non-invasive surgery, cardiac robotics, and smart sensors just earned them a prestigious $250,000 prize.

Pharma giant AbbVie raises its dividend, backed by robust financials and a powerful drug pipeline that signals a thriving post-Humira growth era.

Klothea Bio's trial for a 'longevity protein' drug in Honduras pushes the boundaries of science, but raises questions about offshore research and equity.

The spatial biology leader will unveil its roadmap at AGBT 2026, targeting the next frontiers of drug discovery with 3D imaging and human-relevant models.